Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

Imatinib mesylate (IM) is a small molecule inhibitor of protein tyrosine kinases. In addition to its direct effect on malignant cells, it has been suggested IM may activate of natural killer (NK) cells, hence exerting immunomodulatory functions. In preclinical settings, improved antitumor responses...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Pautier, Patricia, Locher, Clara, Robert, Caroline, Deroussent, Alain, Flament, Caroline, Le Cesne, Axel, Rey, Annie, Bahleda, Ratislav, Ribrag, Vincent, Soria, Jean-Charles, Vassal, Gilles, Eggermont, Alexander, Zitvogel, Laurence, Chaput, Nathalie, Paci, Angelo
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601177/
https://ncbi.nlm.nih.gov/pubmed/23525192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.23079
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars